This position is in the Senior Executive Service (SES), a small elite group of senior government leaders who possess a diverse portfolio of experience and the strong skills required to lead across organizations. This dedicated corps of executives is charged with providing strategic leadership and upholding a commitment to public service that transcends loyalty to a specific agency mission or individual profession. As an SES member you will influence the direction of innovation and transformation of the federal government and lead the next generation of public servants. This position is located in the Food and Drug Administration, Office of Finance, Budget, and Acquisitions in Silver Spring, MD.
Duties – The Director, Office of Acquisitions and Grants Services is responsible for the planning, development, assessment, and execution of procurement and acquisition administrative services for program centers and other organizations within the Food and Drug Administration (FDA), utilizing a business model with negotiated service level agreements. Provides leadership to a staff in the coordination, standardization, and improved service delivery of acquisitions and grants, with specific responsibility for providing technical expertise in the development, implementation and management of critical contracts, simplified acquisitions, technical transfers, grants and cooperative agreement and procurement authorization mechanism. The incumbent will serve as an authority on acquisition and procurement matters, interpreting agency and federal acquisition policies and regulations, establishing clear lines of authority, accountability and responsibility, and resolving all the disagreements in the negotiation process. The incumbent will report to the Chief Financial Officer. Success will be measured based on performance, customer and employee satisfaction… Read More.
G2X TAKE: This position posted last week by FDA to find a new SES level Director to take over as lead for contract activities will leave some wondering what this means for the incumbent Director, Glenda Barfell; and the impact this will have on the future of acquisition activities at FDA. No details have been provided as of yet.
While smaller firms will naturally dismiss this as peripherally interesting, larger firms and those with a significant existing footprint at FDA will be looking to connect with the new leader when added, to help influence the direction this well-funded organization takes, given a plethora of options.
